TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Frequency of CYP2D6 Alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of CYP2D6 Genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success of the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Visual Analog Score - Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net joint torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of non-progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure rate of otomycosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average Clinical Global Impression (CGI) of Overall Change by Physician
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Serum creatinine levels post-surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: BMD at Left Total Hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in QT dispersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Able to Maintain Hemoglobin (Hb) Within 10-12 g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Distant metastasis-free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects completing the survey with evaluable genetic information
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of joint bleeding episodes per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of the OSNA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the OSNA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the OSNA assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of oral water hydration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Hyperhidrosis Disease Severity Scale (HDSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Gravimetric Sweat Production (GSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician's Global Evaluation of Clinical Response (PhGECR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient Incidence of Biopsy-confirmed Acute Rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mRS 0, 1, 2 at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: Change in Mean Daily Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Non-Specific Physical Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental Functional Status
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Glycemic control (HbA1c%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global Aesthetic Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of patients with neurological adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Eradication of Burkholderia dolosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Prevalence of early heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression to serious NEC related morbidity
Endpoint domain: Mortality/survival
Primary endpoint: Chest Tube Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity for R Waves During In-Clinic Recordings at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity for R Waves During In-Clinic Recordings During Treadmill Exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity for R Waves During In-Clinic Recordings During Hand to Hand/Shoulder Maneuvers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive Predictive Value (PPV) for In-Clinic Recordings at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positive Predictive Value (PPV) for In-Clinic Recordings During Treadmill Stress Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Mitoxantrone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of positive COVID-19 cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Blood glucose incremental Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptomatic COVID(+) infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Guideline-appropriate use of antibiotics for upper respiratory tract infection
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Guideline-appropriate use of antibiotics for acute bacterial sinusitis
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Guideline-appropriate use of antibiotics for acute otitis media
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Enteroscopy success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Concentration of Doravirine in Seminal Plasma Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Doravirine in Cervicovaginal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With HIV-1 RNA Seminal Plasma <40 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Quantification of Participants With HIV-1 RNA <40 Copies / mL in Cervicovaginal Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in Mania Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Depression Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in soft tissue mass size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in mean glucagon concentration during hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PANSS change scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Circulating Tumor Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Discontinuations Due to Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Nostril height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nostril width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nostril area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sino-nasal Outcome Test-22 Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Endoscopic Lund-Kennedy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of accordance between the BiPS monitor and the arterial line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores on Visual Analogue Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evoked PESP-BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous PESP-BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of small bowel mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of obstructive and central apneic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients identified at high risk of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Protocol Acceptability Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration-time curve (AUC) of esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Complete or Partial Ablation of the Treated Cyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Death rate in patients discharged after completion of induction chemotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Rate of successful discharge of patients who meet medical discharge criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semantic conflict performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device Reliability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of survival estimate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) or Deaths
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Fibroscan or APRI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Capillary Bleeding Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mental Health State
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Oestradiol Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: oesophageal pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: trans-diaphragmatic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Averaged Pain Severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidents and severity of adverse events reported
Endpoint domain: Adverse events/effects
Primary endpoint: Retrospective Baseline Phe concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 4-Item Neuropsychological Conditions Measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Functional status of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain: Patient-rated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain: clinical exam rated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function: patient-rated
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Function: gait analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytologic grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse-free survival (RFS) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: sodium concentration in skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Daytime Somnolence
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: local stiffness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symbol-Digit Modalities Test performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of ventricular arrhythmias (VAs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to train-of-four (TOF) ratio of 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neuromuscular outcomes
Primary endpoint: Difference in FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time-Weighted Average Daily Change in Viral Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: change in self-reported average pain intensity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Improvement in PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety levels measured by Spielberger State Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of a CHIP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Hamilton Depression Rating Scale (HAMD) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hamilton Rating Scale for Anxiety (HAMA) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in Ambulatory Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Ambulatory Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of TRN-002
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of TRN-002
Endpoint domain: Physiological/clinical
Primary endpoint: Mean Intravaginal Ejaculatory Latency Time (IELT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Ischemic stroke or systemic embolization
Endpoint domain: Mortality/survival
Primary endpoint: Differences in OSA-related variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differences in percentage of mouth puffing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of local and systemic solicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of clinically significant abnormalities in clinical safety laboratory test results reported as unsolicited AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of unsolicited adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of medically attended adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: changes in radiographic bone level (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Score on Railroad Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on Swamp Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Score on President Recognition Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Left liver lobe size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident proportion of capillary leak syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Incident proportion of hemolytic uremic syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Incident proportion of renal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incident proportion of infusion related reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Incident proportion of electrolyte and biochemical abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incident proportion of other medical events related to moxetumomab pasudotox-tdfk interruption or discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Serum concentration of 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Global effect on motor and non motor handicap
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change Response Rate (Partial Response or Better After 2 Cycles)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HCV Sero-prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Long-term failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: IV uptake prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality in neonates
Endpoint domain: Mortality/survival
Primary endpoint: Number of new breast cancer cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stable Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Improvement of Depressive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined Improvement of CVD Risk Factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Toxicity of CAI When Combined With RT
Endpoint domain: Adverse events/effects
Primary endpoint: reaction time in alertness subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hits/misses in Go/NoGo subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reaction time in divided attention subtest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of colorectal adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum autotaxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in systolic and diastolic BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients With SALT50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative mean arterial blood pressure (MAP) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intraoperative heart rate (HR) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: degree of pain perception by patient
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of wound size reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of adverse event (AE) occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Chairside time of brackets bonding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Participants With Overall Stent Thrombosis
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of telemedicine in outpatient visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: General knowledge of anaphylaxis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: number of participants with gastric IM/IN/CA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: stent restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrence of myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Variability of reflexive saccades latencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in BOLD Signal Activation Values Detected in the Reward Circuitry of the Brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tracheobronchitis signs observed on ventilation lung scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in CFU/cm2 on inguinal sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in CFU/cm2 on abdominal sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: number of additional treatments with antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavioral Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stress Mindset Measure - General (SMM-G)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing